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Abstract
Background. With emerging new therapeutic concepts including renal denervation (RDN), there is a renewed interest in resistant hypertension (ResH). Among patients suspected of having ResH, a definitive
diagnosis needs to be established.
Objectives. This study presents observations from a standardized single-center screening program for RDN
candidates, including medical therapy modification and reassessment.
Material and methods. All patients referred to our center for RDN underwent a standardized screening
protocol. Candidates were recruited from among patients receiving no less than 3 antihypertensive drugs,
including diuretics with office blood pressure (BP) >140/90 mm Hg. The assessment included 2 measurements
of BP and ambulatory BP monitoring (ABPM). If needed, pharmacotherapy was intensified and the diagnosis
of ResH was reconfirmed after 6 weeks. If ResH was persistent, patients were hospitalized with repeated
ABPM on day 4. Further, renal CT-angio was performed and a multidisciplinary team discussed the patients’
suitability for RDN.
Results. A total of 87 patients with a ResH diagnosis were referred for RDN. Mean office BP was 159/92
(±7.0/6.5) mm Hg and mean ABPM was 154/90 (±9.0/4.8) mm Hg. The initial medication included angiotensin convertase inhibitors (ACE-I, 78%), angiotensin receptor blockers (12%), β-blockers (85%), calcium
channel blockers (36%), and diuretics (93%). During the 18 months of the RDN program, 5 patients underwent
RDN and 2 further had ineligible renal anatomy. A new diagnosis of secondary hypertension was made
in 21 patients. However, in 59 patients, BP control was achieved after optimization of medical therapy, with
a mean ABPM of 124/74 mm Hg. The final treatment included ACE-I (100%), β-blockers (92%), indapamide
(94%), amlodipine (72%), and spironolactone (61%). Medication in most of these patients (88%) included
single-pill triple combination (52.5%) or double combination (35.6%).
Conclusions. Patients with elevated BP screened for RDN require a rigorous diagnostic workup. Up to 2/3
of patients can be managed with strict pharmacotherapy compliance and pharmaceutical intensification, including single-pill combinations and improved drug compliance. Hasty use of RDN may be a result of poor drug
optimization and/or compliance. It does remain a viable treatment option in thoroughly vetted ResH patients.
Key words: compliance, arterial hypertension, resistant hypertension, renal artery denervation
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Arterial hypertension (HA) remains a major public
health concern with substantial morbidity and mortality, affecting nearly 25% of all adults in the industrialized
world. More specifically, the national health registry data
in Poland suggest that approx. 10.5 million people suffer
from HA, accounting for approx. 32% of the adult population.1 Over the past decades, a great deal of research and
literature has focused on HA leading to a general consensus about the pathomechanisms, pharmacotherapy
and other treatment modalities; however, there remains
a subset of patients that do not benefit from the standard
treatment algorithm. These patients are thought to suffer from resistant hypertension (ResH), which is defined
as blood pressure (BP) that remains above the goal in spite
of optimal doses of 3 antihypertensive agents of different
classes, ideally including a diuretic.2 However, in situations
where elevated office BP is due to white-coat hypertension,
improper BP measurement or medication non-compliance,
patients are considered not to have true ResH, but rather
so-called pseudo-ResH.3
In the case of true ResH, a failure of pharmacotherapy
leads to more invasive methods of treatment, which are
based conceptually on the role of the autonomic nervous
system in the pathogenesis of HA. Initially, invasive techniques involved surgical sympathectomy of abdominal
organs,4 which is usually successful in anti-hypertensive
effects but often results in unbearable gastrointestinal
distress. Thus, a consensus was reached that renal artery
denervation (RDN), a more selective procedure, may be
an option for patients with ResH. The authors of the largest clinical trials examining RDN – HTN 1, 5 HTN 26 and
HTN 37 – established strict inclusion criteria and procedural guidelines for the consideration of RDN. According to the practice-based guidelines, patients suspected
of ResH undergo serial consultations along with confirmatory testing. Due to the complicated screening and verification of clinical suspicions of RDN, there needs to be
a consensus on the diagnosis and final qualification for
RDN therapy. In this paper, the authors seek to analyze
the causes of disqualifications from RDN in patients with
a suspected diagnosis of ResH.

Material and methods
We conducted a prospective study, enrolling
87 consecutive patients with a preliminary diagnosis of ResH who were hospitalized in either
the cardiology or nephrology wards at the Medical University of Lodz, Poland. For the purposes
of the study, ResH was defined as BP that remained above the goal in spite of optimal doses
of 3 antihypertensive agents of different classes,
1 ideally being a diuretic, in accordance with
the most updated guidelines set forth by the European Society of Hypertension and the European

Society of Cardiology.2 Participation in the study required
informed consent, which outlined all the study procedures
and potential side effects. The study protocol was broken
down into multiple phases: a preliminary phase to confirm
the diagnosis of true ResH and a confirmation/hospital
phase. The preliminary phase included screening for true
ResH, composed of a detailed medical history and HA
analysis, outlined in Fig. 1.
Preliminary phase observations helped to exclude patients with a diagnosis of secondary HA or those with
an increased vascular risk (i.e., abdominal aortic aneurysm
or atherosclerosis obliterans) in invasive RDN. The patient
interview was focused on a detailed history of the patient’s
HA and past medical and pharmacotherapy. A small subset
of patients was found to be mismanaged according to treatment guidelines and a definitive diagnosis of ResH could
not be made. In these cases, the pharmacotherapy was optimized and the preliminary stage of the study was repeated after 6 weeks to assess for true ResH. When a diagnosis
of ResH was confirmed during the initial or reassessment
visit (after pharmacotherapy optimization), a patient was
enrolled in the study and admitted to the hospital.
The second phase of the study, considered the confirmation/hospital stage, is outlined in Fig. 2. A continuation
of pharmacotherapy along with routine BP monitoring
was followed by blood tests to further exclude any other
causes of HA or risks in undergoing RDN.
After all inclusion criteria were met, the patients were
screened and qualified to undergo the RDN procedure.
The SymplicityTM renal denervation system (Medtronic,
Dublin, Ireland) was used to carry out the RDN procedure.
Each RDN procedure was conducted by a properly trained
operator – a cardiologist, experienced in percutaneous
coronary angioplasty procedures and supported by a highly qualified licensed technician sent by the manufacturer.
Post-procedure hospitalization lasted an average of 3 days.
Ambulatory BP monitoring (ABPM) and a blood test were
conducted on the last day of hospitalization just before discharge, and again at 6 months (±2 weeks) and 12 months
(±4 weeks). The approval of the Medical University of Lodz
Bioethics Committee/Institutional Review Board was obtained for this study.

2 independent office measurements of arterial blood pressure
• positive qualification when systolic BP was ≥140 mm Hg
or the diastolic BP was ≥90 mm Hg
calculation of estimated glomerular filtration rate (eGFR)
• eGFR score >30mL/min/1.73 m2 was an inclusion criterion
24 h blood pressure monitoring (ABPM)
• positive qualification to screening for RDN when mean systolic BP
was >135 and/or mean diastolic BP was >85 mm Hg
Fig. 1. Preliminary phase testing
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of enrollment, only 5 patients fully satisfied
the inclusion criteria and were qualified to undergo RDN. The primary choice for vascular
double BP measurement bedside, repeated 3 times a day
access was the right femoral artery, and no local
complications were noted after the procedure.
blood sampling: morphology, metabolic panel, liver function
All the patients who underwent the RDN procedure were followed up at 6 and 12 months,
computer tomography angiography of abdominal aorta and renal arteries
in accordance with the protocol. A modification
• in the absence of anatomic aberrations that could interrupt RDN
of pharmacotherapy was required in 1 patient
– a reduction of β-adrenolytic due to asymptomconsultation with endocrinologists and hypertensiologists
atic bradycardia. The treatment of other patients
was not altered during the observation time. Ofexclusion of primary hyperaldosteronism
fice BP and ABPM measurements revealed a reduction of overall BP as compared to the initial
• assessment of electrolytes in blood and urine,
• primary aldosterone concentration measurement,
measurements at the time of enrollment. Blood
• aldosterone concentration measurement after captopril inhibition test
pressure measurements from consecutive visits
are shown in Table 2.
Fig. 2. Hospital procedures of study protocol
The patients that underwent RDN all had satisfactory primary renal function with estimated
Statistical analysis
glomerular filtration rates (eGFR) >60 mL/min/1.73 m2.
There was no significant deterioration of renal function
The quantitative data was compared to a standardized
bell curve with the Kolmogorov–Smirnov test (Lilliefors
Table 1. Demographic and clinical characteristics of the study population
modification). When the data was compatible to normal
Parameter
Mean ±SD
distribution, a mean and standard deviation were used
Age
[years]
63.58
±10.01
(mean ±SD). A variance analysis for dependent samples
Gender (female/male)
33 (37.9%)/54 (62.1%)
was performed. The calculations were carried out on MedCalc Statistical Software v. 17.11.5 (MedCalc Software
Diabetes mellitus type 2
22 (25.3%)
bvba, Ostend, Belgium).
Coronary artery disease
24 (27.6%)
continuation of pharmacotherapy

Results

Hypercholesterolemia

23 (26.4%)

Atrial fibrillation

11 (12.6%)

History of stroke

A total of 87 patients (33 female, 54 male) were enrolled
in the study. The demographics are shown in Table 1.
The mean office BP measurement in the study group was
159/92 (±8.7/6.5) mm Hg and the mean ABPM measurement was 154/90 (±9/4.8) mm Hg. During the 18 months

8 (9.2%)
2

eGFR (MDRD) [mL/min/1.73 m ]

73.67 ±23.11

Creatinine [mg/dL]

1.06 ±0.29

Time of HA therapy [years]

15.01 ±5.99

SD – standard deviation; eGFR – estimated glomerular filtration rate;
MDRD – eGFR estimation formula; HA – arterial hypertension.

Table 2. Office BP measurements and ABPM measurements during the follow-up period in patients that underwent RDN
Parameter

M0 BP
(mean ±SD)

M6 BP
(mean ±SD)

M12 BP
(mean ±SD)

p-value

134.70 ±4.40

130.50 ±1.32

<0.001

85.10 ±4.55

81.60 ±6.19

0.14

Mean office BP measurements
Systolic BP

158.80 ±6.40

Diastolic BP

88.30 ±4.56

ABPM results
24-hour systolic BP

141.40 ±4.83

127.60 ±8.38

130.60 ±6.39

0.015

24-hour diastolic BP

82.60 ±4.34

70.80 ±7.82

71.20 ±6.30

0.026

Systolic BP – day

145.00 ±5.24

132.20 ±11.67

135.40 ±6.19

0.017

Diastolic BP – day

86.20 ±5.26

75.80 ±10.71

75.60 ±7.50

0.053

Systolic BP – night

132.00 ±4.36

120.20 ±5.50

123.00 ±4.18

0.049

Diastolic BP – night

75.80 ±6.91

61.60 ±7.86

65.40 ±5.90

0.088

BP – blood pressure; M0, M6, M12 – consecutive follow-up visits at the end of hospitalization, after 6 and 12 months post hospitalization; SD – standard
deviation; ABPM – ambulatory blood pressure monitoring.
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in the follow-up period. The eGFR values based on the Modification of Diet in Renal Disease (MDRD) Study Equation
are shown in Table 3.
There were 82 patients that did not qualify for RDN procedure, all with a diagnosis of elevated BP despite optimal
pharmacotherapy. The mean office BP measurements and
mean ABPM scores for this group are shown in Table 4. For
the patients who were disqualified from RDN, the reasons
have been outlined in Table 5.
Secondary hypertension due to various etiologies was
diagnosed in 21 (25.6%) of disqualified patients. The most
frequent cause of secondary hypertension was a significant stenosis of at least 1 of the renal arteries (12 cases
(14.6%)). These patients were advised to continue with
a diagnostic workup and treatment with vascular surgery. Seven patients (8.5%) were found to have primary
Table 3. The eGFR values of the patients who underwent renal
denervation calculated with the MDRD formula in mL/min/1.73 m2
Patient
No.

eGFR
(baseline)

eGFR
(at 6 months)

eGFR
(at 12 months)

1

105.37

100.88

117.45

2

85.01

89.29

87.81

3

77.50

72.69

83.93

4

85.64

91.10

87.75

5

80.81

76.17

75.08

eGFR – estimated glomerular filtration rate; eGFR 0, 6, 12 – values
of estimated glomerular filtration rate during the first visit and during
follow-up visits in the 6th and 12th month.
Table 4. Office BP measurements and ABPM measurements during
the follow-up period in patients disqualified from RDN
Parameter

Mean +SD

Mean office BP measurements
Systolic BP

159.20 ±8.88

Diastolic BP

92.20 ±6.54
ABPM results

24-hour systolic BP

153.95 ±8.89

24-hour diastolic BP

89.86 ±4.56

Systolic BP – day

158.45 ±8.89

Diastolic BP – day

91.44 ±6.15

Systolic BP – night

149.38 ±8.96

Diastolic BP – night

88.27 ±7.06

RDN – renal denervation; BP – blood pressure; SD – standard deviation;
ABPM – ambulatory blood pressure monitoring.
Table 5. Main causes of disqualification from renal denervation during
screening (number of patients)
• Non-optimal pharmacotherapy (59)
• Secondary hypertension (21)
– significant stenosis in renal artery (12)
– primary hyperaldosteronism (7)
– active adrenal adenoma (2)
• Renal artery anatomy improper to RDN procedure (2)

hyperaldosteronism and 2 (2.4%) were discovered to have
an active adrenal aldosterone-secreting adenoma and were
referred to endocrinologists. Another 2 patients (2.4%)
had an abnormal renal artery diameters and kidneys with
multiple vascular supplies.
Another 59 patients (72%) were diagnosed with pseudo-ResH, defined as an initial diagnosis of ResH but with
suboptimal pharmacotherapy or patient noncompliance.
At the end of the screening phase, optimization of therapy
and counseling on compliance lead to this group achieving
a satisfactory BP and disqualification from RDN. All the patients diagnosed with pseudo-ResH had initial BP measurements that could qualify them for RDN. The mean office BP
and ABPM scores in the screening phase and after final effective pharmacotherapy administration are shown in Table 6.
In this pseudo-resistant group, a satisfactory BP was
achieved at various points in the screening process. In all
cases, pharmacotherapy was optimized during the initial screening visit and BP measurements were repeated
at 6 weeks. The majority of patients (36) achieved satisfactory BP measurements at this point. In 23 of these cases,
ResH was the working diagnosis until the first hospitalization. Despite some patients having BP measurements
that qualified for RDN during the initial screening, not all
of them were treated with diuretics. The pharmacotherapy
regimen of the screening failure group on presentation
and final pharmacotherapy regimen are shown in Fig. 3,4.
In most cases, the addition of hypertensive therapy was
based on single-pill combinations with 2 or 3 substances.
In 31 patients (52.5%), we chose a triple combination pill of perindopril, amlodipine and indapamide. In 21 patients (35.6%)
a combination pill of perindopril and amlodipine was utilized.
In summary, an initial diagnosis of ResH was ruled out
due to the discovery of reversible causes of high BP in 82
cases (94%). Improper treatment or noncompliance issues
were the cause of this in 59 of the patients (68%).
Table 6. Office BP measurements and ABPM measurements including
BP scores during the screening and final BP final scores after new
pharmacotherapy optimization
Parameter

BP screening
scores
(mean ±SD)

BP final scores
(mean ±SD)

p-value

Mean office BP measurements
Systolic BP

158.6 ±8.0

125.30 ±5.81

Diastolic BP

93.4 ±5.4

81.70 ±4.45

<0.001

ABPM results
24-hour systolic BP

153.3 ±7.9

123.9 ±1.9

24-hour diastolic BP

89.9 ±4.7

74.4 ±1.9

Systolic BP – day

157.8 ±7.9

129.6 ±2.5

Diastolic BP – day

91.6 ±6.5

79.6 ±2.5

Systolic BP – night

148.7 ±8.0

118.3 ±3.3

Systolic BP – night

88.2 ±6.9

69.3 ±3.0

<0.001

BP – blood pressure; SD – standard deviation; ABPM – ambulatory blood
pressure monitoring.
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93%

85%

78%

36%
12%
ACI

ARB

CCB

β-adrenolycs

diurecs

Fig. 3. Initial pharmacotherapy in patients with pseudoresistant
hypertension
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92%

94%
72%

60%

61%

40%
20%
0%

ACI

β-adrenolics

indapamide

amlodipine

spironolactone

Fig. 4. Final pharmacotherapy in patients with pseudoresistant
hypertension

Discussion
Resistant hypertension presents a clinical challenge often requiring an arduous diagnostic workup, pharmacovigilance, optimization of anti-hypertensive medications,
and a detailed medical history to rule out non-compliance.
Our study, to the best of our knowledge, is the first to analyze a population of patients initially presenting with
a presumed diagnosis of ResH that in actuality suffered
from uncontrolled hypertension caused by suboptimal
pharmacotherapy or poor compliance issues.
Symplicity HTN-1 was the first clinical trial examining percutaneous transcatheter RDN in the treatment
of ResH.4 The study consisted of a cohort of 50 patients
who underwent RDN; a sustainable BP lowering effect was
observed during consecutive follow-up visits at 1, 3, 6, 9, and
12 months. The cohort was then increased to 153 patients
and the follow-up period was extended to 3 years.8 The hypotensive effect of RDN was still present 36 months from
the date of the procedure. Blood pressure measurements
were on average 32 mm Hg lower for systolic BP and 14.4 mm
Hg lower for diastolic BP as compared to the measurements
at the initial screening. It was observed that the percentage
of local femoral site complications was not any higher than
those in similar procedures such as coronary angiography.
Renal denervation did not have a negative impact on renal
function. Other studies have also reported similar observations.9 Nevertheless, RDN is an invasive procedure and
should only be performed in definitive cases of ResH.
There should be no ambiguity in the qualification of patients with ResH for RDN procedures. The results of our

study show that ineffective medical therapy with 3 or more
hypotensive drugs (including diuretics) is not enough to establish a definitive diagnosis. High BP in an outpatient setting may be a symptom of various disorders or of psychosomatic causes such as “white coat hypertension”, which may
be defined as persistently elevated BP (≥140/90 mm Hg)
“in the presence of a healthcare worker, particularly a physician” in patients not taking medication, with an average
awake ABPM < 135/85 mm Hg.10 To obtain unadulterated
objective measurements of BP, 24-hour ABPM is required.11
When suboptimal BP control is confirmed, it still requires
exclusion of potentially reversible causes of HA. In our study
25.6% of the RDN disqualifications were caused by potentially reversible or secondary causes of hypertension, which generally have a prevalence of 5–10% in hypertensive patients.12
Renal diseases such as renal artery disease, glomerular and
tubular diseases are responsible for almost 50% of cases
of secondary hypertension.12 It is also important to note
that diseases with significant deterioration of glomerular
filtration excluded most of these patients from the RDN
procedure in our study. Patients with serious renal artery
stenosis need a more significant diagnostic workup due
to stimulation of the renin-angiotensin-aldosterone system.
As demonstrated by our study and the literature, exclusion
of secondary causes of HA is necessary. The most common
and available methods to exclude this diagnosis are imaging
techniques, most commonly renal Doppler ultrasonography.13
An RDN screening requires more specific methods that can
in addition visualize the aorta and femoral arteries. Computed
tomography (CT) with contrast is more appropriate, providing precise vascular imaging and providing visualization
of the kidneys and adrenal glands to rule out any possible pathologies. Appreciation of the quantity and diameter of renal
arteries is also necessary in preparing for RDN. In addition,
renal and adrenal gland anomalies may be responsible for high
BP which may be confirmed through imaging techniques.
Another significant cause of HA are pathologies resulting in the disruption of normal hormonal activity.14 In our
study, we excluded 2 patients from RDN due to the presence of adrenal tumors discovered using CT. Detailed examination and diagnostic workup confirmed the hormonal,
aldosterone-exerting activity of these tumors. Other patients
with endocrine-disrupting properties had either primary
hypertrophy of the renal cortex or primary hyperaldosteronism, diagnosed in 7 subjects in this group. Computed
tomography was not useful in these cases, but, as the literature suggests, renal scintigraphy is more specific.15 Renal
artery anatomy is another important issue that can influence
the course, effectiveness and safety of the renal denervation procedure. Short, bendy and narrow vessels should be
noted and may exclude patients from RDN.16 Furthermore,
there is a group of patients with more than 1 artery supplying
blood to the kidney. The general prevalence of this anomaly
is seen in up to 28%17 or 34%13 of patients with HA. In our
study, we disqualified 2 patients from undergoing RDN due
to the presence of multiple renal arteries in 1 kidney.
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The most common reason for disqualification from
RDN in our study was inappropriate or suboptimal medical therapy which was identified in the initial screening
phase of the study. In 72% of the cases, modifications
of pharmacotherapy led to optimized BP control. A detailed medical history interview often revealed multiple
therapeutic modifications leading to non-compliance.
Numerous studies have been performed over the past decades discussing patient attitudes and compliance. It has
been reported that satisfactory compliance is seen in only
about 50% of cases. Partial compliance is seen in approx.
30–40% of patients, and 5–10% admit that they take their
drugs selectively or do not take them at all.18 Achievement
of optimal BP control by adding another drug as opposed
to increasing the dose of the current regimen is a strategy confirmed by numerous studies.19 On the other hand,
the effectiveness of therapy increases when the number
of pills is reduced.20,21 The only way to reconcile these
issues is single-pill combination therapy.19 In our study,
patients disqualified from RDN during the initial screening phase due to potential drug compliance issues were
ultimately transitioned to a single-pill triple combination (52.5%) or single-pill double combination (35.6%).
In 28% of our cases, optimal BP control was achieved with
the initiation of new pharmacotherapy, but only during
the hospitalization period. These findings affirmed that
drug compliance was the most important cause of false
positive reports of ResH.

Conclusions
Renal artery denervation is an innovative method
of treatment for ResH but remains debated, and its indication is decreasing. Improvements in technical skill
and greater availability of devices for performing RDN
are necessary. Additional studies must also be performed
to further assess the benefits of the procedure.
The presence of uncontrolled high BP does not automatically warrant a diagnosis of ResH, regardless of duration.
Such cases always require thorough diagnostic testing
to exclude secondary causes of hypertension. It is the up
to the due diligence of healthcare workers to provide
a conscientious choice of pharmacotherapy, taking into
account the patient’s capabilities and needs, to allow for
good compliance.
Analyzing the methodology of our study, we hypothesize that the best way to achieve compliance is singlepill combinations of anti-hypertensives, but larger studies
focused on the issues of compliance are required to verify
this assumption.
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